These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 23488108)

  • 1. Price pressure. As the number of costly specialty drugs grows, insurers and providers push for more reasonable alternatives.
    Evans M
    Mod Healthc; 2013 Jan; 43(4):6-7, 16, 1. PubMed ID: 23488108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growing pains. Insurers and PbMs want in on 340B savings.
    Lee J
    Mod Healthc; 2012 Mar; 42(11):10. PubMed ID: 22462315
    [No Abstract]   [Full Text] [Related]  

  • 3. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4 payer trends to control specialty pharmacy costs.
    Studin I
    Manag Care; 2012 May; 21(5):27-9. PubMed ID: 22670484
    [No Abstract]   [Full Text] [Related]  

  • 5. Pricing and reimbursement of pharmaceuticals in Italy.
    Folino-Gallo P; Montilla S; Bruzzone M; Martini N
    Eur J Health Econ; 2008 Aug; 9(3):305-10. PubMed ID: 18566845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Employers push to manage prescription drug costs.
    Frieden J
    Bus Health; 1992 May; 10(6):43-6, 48, 50. PubMed ID: 10119119
    [No Abstract]   [Full Text] [Related]  

  • 7. Prescription drug prices in Canada.
    Gross D
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2003 Jun; (IB62):1-22. PubMed ID: 12807123
    [No Abstract]   [Full Text] [Related]  

  • 8. Pricing and reimbursement of pharmaceuticals in Sweden.
    Jönsson B
    Pharmacoeconomics; 1994; 6 Suppl 1():51-60. PubMed ID: 10172482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited options to manage specialty drug spending.
    Tu HT; Samuel DR
    Res Brief; 2012 Apr; (22):1-13. PubMed ID: 23155549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative analysis of the impact of a positive list system on new chemical entity drugs and incrementally modified drugs in South Korea.
    Ha D; Choi Y; Kim DU; Chung KH; Lee EK
    Clin Ther; 2011 Jul; 33(7):926-32. PubMed ID: 21715008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Can linking co-payment for drugs to evidence on treatment value improve health outcomes and contain healthcare costs?].
    Triki N; Pliskin JS; Greenberg D
    Harefuah; 2010 Aug; 149(8):524-8, 550. PubMed ID: 21341433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eliminating fixed costs: Part I--Health system drivers.
    Weil TP
    Manag Care Interface; 2002 Aug; 15(8):27-32, 53. PubMed ID: 12229063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consumers face higher costs as health plans seek to control drug spending.
    Mays GP; Hurley RE; Grossman JM
    Issue Brief Cent Stud Health Syst Change; 2001 Nov; (45):1-4. PubMed ID: 11865903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolving pharmacy benefit market.
    Navarro RP
    Med Interface; 1994 May; 7(5):65-7, 70. PubMed ID: 10134345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incentives in the Medicare prescription drug benefit.
    Natl Bur Econ Res Bull Aging Health; 2006; (15):1-2. PubMed ID: 16805056
    [No Abstract]   [Full Text] [Related]  

  • 16. Can health care costs be contained? Yes, says one third party fiscal intermediary.
    Kaplan SX
    Empl Benefits J; 1978; 3(4):10-3, 15. PubMed ID: 10294880
    [No Abstract]   [Full Text] [Related]  

  • 17. The association of insurance type with costs of dispensed drugs.
    Mott DA; Kreling DH
    Inquiry; 1998; 35(1):23-35. PubMed ID: 9597015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choices in prescription-drug benefit programs: mail versus community pharmacy services.
    Kirking DM; Ascione FJ; Richards JW
    Milbank Q; 1990; 68(1):29-51. PubMed ID: 2215427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. As drug payment model changes, confusion grows among insurers.
    Sipkoff M
    Manag Care; 2007 Feb; 16(2):56-9. PubMed ID: 17361511
    [No Abstract]   [Full Text] [Related]  

  • 20. Managing the intricate Web of prescription drugs.
    Eber BL
    Benefits Q; 2003; 19(1):45-50. PubMed ID: 12608118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.